India Exchange Filings

Q2 FY27 Results and Management Appointment

Supriya Lifescience Ltd reports Q2 FY27 revenue of ₹206.30 crore and appoints Mangesh Vaze as COO

  • Revenue rose 8.7% sequentially and 3.2% year on year; net profit was ₹29.25 crore, up 21.7% sequentially and down 42.0% year on year.
  • Operating margin was approximately 17.4%; no exceptional items were reported.
  • Vaze’s appointment as COO and Senior Management Personnel is effective November 6, 2026; the limited review report was unqualified.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.